Madrigal Pharmaceuticals, Inc. — Cyborg Score 7/10
Strong
Biopharmaceuticals - Hepatology/Metabolic Disease
Strategic Profile
Madrigal has achieved rapid Rezdiffra revenue growth, now annualizing above $1 billion with a strong first-mover advantage in MASH. The pipeline now exceeds 10 programs anchored by Rezdiffra, with recent licensing deals for complementary mechanisms including ervogastat, a Phase 2 oral DGAT-2 inhibitor and MGL-2086, an oral GLP-1 receptor agonist entering first-in-human studies in Q2 2026.
Cyborg Score Rationale
Rezdiffra revenues annualize above $1 billion with strong first-mover advantage in MASH, but despite robust sales, MDGL remains unprofitable and faces intensifying competition from GLP-1 drugs and emerging FGF21 inhibitors. Expanding pipeline and strategic partnerships support growth potential.
Top Insights
Pipeline expanded to >10 programs with $60M upfront payment and up to $4.4B in milestone payments for six siRNA programs
Faces intensifying competition from GLP-1 drugs and FGF21 inhibitors, though management highlights large untapped patient pool
Phase 3 outcomes trial evaluating Rezdiffra for compensated MASH cirrhosis (F4c) is fully enrolled
Active hiring and equity grants indicate expansion; recent grants to 40+ new employees across 2025-2026
Named Competitors
GLP-1 Receptor Agonists — Competing diabetes/obesity medications being studied in MASH
FGF21 Inhibitors — Emerging mechanism competing in MASH treatment space
Rezdiffra — First-approved MASH treatment with >$1B run-rate revenue
Recent Developments
(February 2026) Exclusive global license agreement for six preclinical siRNA programs from Ribo with $60M upfront
(January 2026) Exclusive global license for ervogastat (Phase 2 DGAT-2 inhibitor) from Pfizer with $50M upfront
(January 2026) GLP-1 agonist (MGL-2086/SYH2086) scheduled to enter first-in-human studies Q2 2026
Open the full interactive Madrigal Pharmaceuticals, Inc. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.